OKUR
OnKure Therapeutics, Inc.Company Information
- Company Name
- OnKure Therapeutics, Inc.
- CIK
- CIK0001637715
- Category
- <br>Emerging growth company
- Ticker: Exchange
- OKUR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- OKUR
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-15
- Last sale
- 2026-09-21
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,945
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 34,892,588
- Shares outstanding
- 49,869,177
- Ownership
- 69.97%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- -7.56%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 167 | 192 | 59 | 70 | 83 | 97 | 111 | 61 | 36 | 20 | 30 | 12 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | 16 | 41 | 62 | 75 | 114 | ||||||
| Available For Sale Securities Debt Securities Current | 10 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 5 | 2 | 1 | 1 | 2 | 2 | 0 | 1 | 1 | 4 | 3 | ||||||
| Assets Current | 178 | 197 | 61 | 72 | 85 | 98 | 113 | 77 | 78 | 84 | 34 | 129 | ||||||
| Property Plant And Equipment Net | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 179 | 199 | 62 | 73 | 86 | 100 | 115 | 78 | 79 | 85 | 36 | 130 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 11 | 1 | 1 | 2 | 2 | 3 | 0 | 0 | 1 | 3 | 2 | ||||||
| Accrued Liabilities Current | - | - | - | - | 5 | 6 | 7 | 1 | 1 | 2 | 4 | 11 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 4 | 3 | 4 | 4 | - | - | 7 | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 7 | 14 | 6 | 6 | 8 | 9 | 11 | 3 | 1 | 3 | 7 | 14 | ||||||
| Operating Lease Liability Noncurrent | 1 | 0 | - | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | ||||||
| Deferred Compensation Liability Classified Noncurrent | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Liabilities | 7 | 14 | 6 | 6 | 8 | 9 | 11 | 4 | 2 | 3 | 8 | 15 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Value | - | - | - | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Additional Paid In Capital | 417 | 414 | 270 | 267 | 264 | 261 | 259 | 310 | 309 | 308 | 0 | 305 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | - | - | - | - | - | - | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -245 | -229 | -214 | -201 | -186 | -171 | -155 | -236 | -232 | -227 | -102 | -191 | ||||||
| Stockholders Equity | 172 | 184 | 56 | 66 | 78 | 91 | 104 | -135 | -124 | -111 | -102 | 115 | ||||||
| Liabilities And Stockholders Equity | 179 | 199 | 62 | 73 | 86 | 100 | 115 | 78 | 79 | 85 | 36 | 130 | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | - | - | 210 | - | - | - | 210 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | - | - | - | - | - | - | - | 3 | 3 | 3 | 3 | 3 | ||||||
| Shares Outstanding | - | - | - | - | - | - | - | 3 | 3 | 3 | 3 | 3 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | - | - | - | ||||||
| Preferred Stock Shares Authorized | - | - | 10 | - | - | - | 10 | - | - | - | - | - | ||||||
| Preferred Stock Shares Issued | - | - | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | 0 | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialOnKure Therapeutics, Inc. (OKUR) — SEC Financial Statements & Analysis
OnKure Therapeutics, Inc. (OKUR) is a pharmaceutical preparations company, incorporated in DE. OnKure Therapeutics, Inc. trades on Nasdaq as: OKUR. OnKure Therapeutics, Inc. (OKUR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, OnKure Therapeutics, Inc. carries a market cap of $227.40M, a P/E ratio of -3.87x, a P/B ratio of 1.32x, a P/S ratio of 66.05x, an enterprise value of $60.90M, and an EV/EBITDA multiple of -0.99x. On profitability, it posts an operating margin of -1804.82%, a net margin of -1705.05%, a Return on Equity (ROE) of -46.91%, a Return on Assets (ROA) of -44.24%, and a Return on Invested Capital (ROIC) of -23152.01%. Per share, it reports EPS of $-1.18, diluted EPS of $-1.18, free cash flow per share of $-0.96, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -1.54% year-over-year, net income growth of -2.67% year-over-year, and EPS growth of -73.63% year-over-year. On the balance sheet, it maintains a current ratio of 26.75x, a quick ratio of 26.55x, working capital of $171.03M, a debt-to-equity ratio of 0.04x, a debt ratio of 0.04, an interest coverage ratio of -18.09x, free cash flow of $-47.86M (TTM), and net debt of $-166.50M. Figures sourced from SEC EDGAR.
- Market Cap
- $227.40M
- P/E TTM
- -3.87x
- EPS TTM
- $-1.18
- P/B TTM
- 1.32x
- ROE TTM
- -46.91%
- ROA TTM
- -44.24%
- Debt To Equity
- 0.04x
- Free Cash Flow TTM
- $-47.86M
- Net Revenue TTM Growth 1Y
- -1.54%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is OnKure Therapeutics, Inc. in?
OnKure Therapeutics, Inc. (OKUR) operates in the Pharmaceutical Preparations industry.
What exchange does OKUR trade on?
OnKure Therapeutics, Inc. (OKUR) trades on the Nasdaq.
Where is OnKure Therapeutics, Inc. incorporated?
OnKure Therapeutics, Inc. is incorporated in DE.
When was OnKure Therapeutics, Inc. (OKUR)'s most recent SEC filing?
OnKure Therapeutics, Inc. (OKUR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is OKUR's market cap?
OnKure Therapeutics, Inc. (OKUR) has a market capitalization of $227.40M as of 2026-06-30.
What is OKUR's EPS (earnings per share)?
OnKure Therapeutics, Inc. (OKUR)'s trailing twelve month EPS is $-1.18 as of 2026-06-30.
What is OKUR's ROE (return on equity)?
OnKure Therapeutics, Inc. (OKUR)'s trailing twelve month Return on Equity (ROE) is -46.91% as of 2026-06-30.
What is OKUR's ROA (return on assets)?
OnKure Therapeutics, Inc. (OKUR)'s trailing twelve month Return on Assets (ROA) is -44.24% as of 2026-06-30.
What is OKUR's ROIC (return on invested capital)?
OnKure Therapeutics, Inc. (OKUR)'s trailing twelve month Return on Invested Capital (ROIC) is -23152.01% as of 2026-06-30.
What is OKUR's EV/EBITDA?
OnKure Therapeutics, Inc. (OKUR)'s trailing twelve month EV/EBITDA is -0.99x as of 2026-06-30.